Crescendo Pharmaceuticals

Crescendo Biologics is a biopharmaceutical company that was based in Cambridge, UK, specializing in the development of novel, targeted T cell enhancing therapeutics. The company's core technology is the Humabody platform, which utilizes a proprietary transgenic mouse to generate fully human VH domain building blocks that are smaller and more modular than traditional antibodies. Its lead candidate, CB307, is a bispecific Humabody targeting PSMA and CD137, designed to activate T cells specifically within the tumor microenvironment for the treatment of PSMA-positive solid tumors. Crescendo established high-value collaborations with major partners such as Takeda, BioNTech, and Zai Lab to apply its platform across oncology and inflammatory indications. However, following clinical and funding challenges in early 2025, the company reportedly closed its laboratory operations and its leadership team transitioned to other ventures.